$Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report$

Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report

<p>Abstract</p> <p>Background</p> <p>Multiple sclerosis (MS) is considered an autoimmune disease of the central nervous system and therapeutic inhibition of leukocyte migration with natalizumab, an anti-alpha4 integrin antibody, is highly effective in patients with MS....

Full description

Bibliographic Details
Main Authors:	Constantin Gabriela, Murrighile Maria R, Sotgiu Stefano
Format:	Article
Language:	English
Published:	BMC 2010-09-01
Series:	BMC Neurology
Online Access:	http://www.biomedcentral.com/1471-2377/10/84

Similar Items

Natalizumab in patients with multiple sclerosis in Colombia: a case series
by: Juan Raúl García Bonitto, et al.
Published: (2020-06-01)

Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC)
by: E. V. Popova, et al.
Published: (2014-12-01)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
by: Ilaria Callegari, et al.
Published: (2023-01-01)

[Translated article] Refractory Eosinophilic Fasciitis: Good Response to Ocrelizumab in a Patient with Multiple Sclerosis Under Treatment with Natalizumab
by: B. Vázquez Losada, et al.
Published: (2024-11-01)

Best practice in the use of natalizumab in multiple sclerosis
by: Óscar Fernández
Published: (2013-03-01)

Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study
by: Stephenson Judith J, et al.
Published: (2012-12-01)

Multiple Sclerosis Treatment with Natalizumab: Analysis of a Hospital-Based Cohort
by: Ana Teresa Carvalho, et al.
Published: (2014-08-01)

Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
by: Smaranda Maier, et al.
Published: (2020-10-01)

Natalizumab: increased vigilance is required in treating patients with multiple sclerosis
by: Michael K. Racke, et al.
Published: (2008-11-01)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
by: Robert Hoepner, et al.
Published: (2014-01-01)

Influence of natalizumab on resting-state connectivity in patients with multiple sclerosis
by: Diogo G. Corrêa, et al.
Published: (2023-08-01)

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
by: Gatzonis Stylianos, et al.
Published: (2009-08-01)

Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring
by: Kathy Khoy, et al.
Published: (2020-09-01)

An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations
by: Kornek B
Published: (2015-05-01)

Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers
by: Enedina Maria Lobato de Oliveira, et al.
Published: (2015-09-01)

The effectiveness of Natalizumab on MRI outcome measures in patients with relapsing multiple sclerosis
by: Dalton, C, et al.
Published: (2003)

Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients.
by: Karen Yao, et al.
Published: (2008-01-01)

Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
by: Lars Henrik Dahl Hamnvik, et al.
Published: (2024-05-01)

A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis
by: Pietro Iaffaldano, et al.
Published: (2024-08-01)

Natalizumab promotes anti-inflammatory and repair effects in multiple sclerosis.
by: Ragnhild Reehorst Lereim, et al.
Published: (2024-01-01)

Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
by: Ranjani Ganapathy Subramanian, et al.
Published: (2021-11-01)

Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis
by: Finn Sellebjerg, et al.
Published: (2016-01-01)

Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis
by: Véronique Ferret-Sena, et al.
Published: (2016-01-01)

3 Managing disease activity during treatment with natalizumab in relapsing-remitting multiple sclerosis
by: Nevin John, et al.
Published: (2024-08-01)

Insight into motor fatigue mechanisms in natalizumab treated multiple sclerosis patients with wearing off
by: Giorgio Leodori, et al.
Published: (2024-07-01)

Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates
by: Arwa Rekik, et al.
Published: (2022-05-01)

Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
by: Julia Krämer, et al.
Published: (2017-01-01)

A comparison of natalizumab’s effects on SDMT between pediatric-onset and adult-onset multiple sclerosis patients
by: Marco Puthenparampil, et al.
Published: (2024-11-01)

Clinical Experience with Dimethyl Fumarate and Natalizumab in Pregnant Women with Multiple Sclerosis: A Four-Patient Case Series
by: Satoshi Saito, et al.
Published: (2024-01-01)

JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients
by: Mancuso Roberta, et al.
Published: (2012-12-01)

Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients
by: Jan W. Traub, et al.
Published: (2019-11-01)

Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-β
by: Úrsula Muñoz, et al.
Published: (2022-08-01)

Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy
by: Roberto Bergamaschi, et al.
Published: (2024-06-01)

Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis
by: Marco Puthenparampil, et al.
Published: (2023-06-01)

Surgical treatment of pediatric tuberous sclerosis complex complicated with refractory epilepsy: A case report
by: Jiajia Yu, et al.
Published: (2025-02-01)

The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
by: Roberto De Masi, et al.
Published: (2021-01-01)

Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
by: Diego Cadavid, et al.
Published: (2013-01-01)

Early Magnetic Resonance Detection of Natalizumab-Related Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Sclerosis
by: Guglielmo Manenti, et al.
Published: (2013-01-01)

Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
by: Tim Sinnecker, et al.
Published: (2016-01-01)

Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
by: Yara Dadalti Fragoso, et al.
Published: (2016-08-01)